Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients
In this MEDtalk, dr. Roch Houot, Universitéde Rennes, France, presents results addressing the safety and efficacy of axicabtagene ciloleucel as second-line therapy in patients with aggressive B-cell lymphoma, not candidates for HDCT/ASCT. Treatment with axicabtagene ciloleucel results in a high response rate and durable remissions in the group of patients with poor prognostic features (primary refractory or early relapse). At the same time, this combination has an acceptable safety profile.
